| 1 |
Martin GS，Mannino DM，Eaton S，et al. The Epidemiology of sepsis in the United States from 1979 through 2000 ［J］. N Engl J Med，2003，348（16）：1546-1554.
|
| 2 |
Ma J，Liao XL，Luo B，et al. Role of apolipoprotein A-I in protecting against endotoxin toxicity［J］. Acta Biochim Biophys Sinica，2004，36（6）：419-424.
|
| 3 |
Gupta H，Dai L，Datta G，et al. Inhibition of lipopolysaccharideinduced inflammatory responses by an apolipoprotein AI mimetic peptide［J］.Circ Res，2005，97（3）：236-243.
|
| 4 |
Henning MF，Herlax V，Bakas L. Contribution of the C-terminal end of apolipoprotein AI to neutralization of lipopolysaccharide endotoxic effect［J］.Innate Immun，2011，17（3）：327-337.
|
| 5 |
Li Y，Dong JB，Wu MP. Human ApoA-Ⅰ overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice［J］.Eur J Pharmacol，2008，590（1-3）：417-422.
|
| 6 |
Yan Y，Li Y，Lou B，et al. Beneficial effects of ApoA-Ⅰ on LPSinduced acute lung injury and endotoxemia in mice［J］. Life Sci，2006，79（2）：210-215.
|
| 7 |
Wang L，Chen WZ，Wu MP.Apolipoprotein A-I inhibits chemotaxis，adhesion，activation of THP-l cells and improves the plasma HDL inflammatory index［J］.Cytokine，2010，49（2）：194-200.
|
| 8 |
Barlage S，Frohlich D，Bottcher A，et al. ApoE-containing high density lipoproteins and phospholipid transferprotein activity increase in patients with a systemic inflammatory response［J］. J Lipid Res，2001，42（2）：281-290.
|
| 9 |
Berbée JF，vander Hoogt CC，Kleemann R，et al.Apolipoprotein C-I stimulates the response to lipopolysaccharide and reduces mortality in gram-negative sepsis［J］.FASEB J，2006，20（12）：2162-2164.
|
| 10 |
Berbée JF，van der Hoogt CC，Sundararaman D，et al. Severe hypertriglyceridemia in human APOC-I transgenic mice is caused by apoC-I-induced inhibition of LPL ［J］. J Lipid Res，2005，46（2）：2 9 7-3 0 4.
|
| 11 |
Conde-Knape K，Bensadoun A，Sobel JH，et al. Overexpression of apoC-I in apoE-null mice： severe hypertriglyceridemia due to inhibition of hepatic lipase［J］.J Lipid Res，2002，43（12）：2136-2145.
|
| 12 |
Shachter NS. Apolipoproteins C-I and C-Ⅲ as important modulators of lipoprotein metabolism［J］.Curr Opin Lipidol，2001，12（3）：297-304.
|
| 13 |
Berbée JF，Coomans CP，Westerterp M，et al. Apolipoprotein CI enhances the biological response to LPS via the CD14/TLR4 pathway by LPS-binding elements in both its N-and C-terminal helix［J］. J Lipid Res，2010，51（7）：1943-1952.
|
| 14 |
Fu P，Wang AM，He LY，et al. Elevated serum ApoE levels are associated with bacterial infections in pediatric patients［J］.J Microbiol Immunol Infect，2014，47（2）：122-129.
|
| 15 |
Li L，Thompson PA，Kitchens RL. Infection induces a positive acute phase apolipoprotein E response from a negative acute phase gene：role of hepatic LDL receptors［J］. 2008，J Lipid Res，2008，49（8）：1 7 8 2-1 7 9 3.
|
| 16 |
Wang C，Wang Y，Wang A，et al.The diagnostic value of apolipoprotein E in pediatric patients with invasive bacterial infections［J］. Clin Biochem，2012，45（3）：215-218.
|
| 17 |
Zhang HL，Wu LM，Wu J. Cross-talk between Apolipoprotein E and cytokines［J］.Mediators Inflamm，2011，2011：949072.
|
| 18 |
Kattan OM，Kasravi FB，Elford EL，et al. Apolipoprotein E-mediated immune regulation in sepsis［J］.Immunology，2008，181（2）：1399-1408.
|
| 19 |
van den Elzen P，Garg S，Leon L，et al. Apolipoprotein-mediated pathways of lipid antigen presentation［J］. Nature，2005，437（7060）：9 0 6-91 0.
|
| 20 |
Kelley I. Chuang，Briana Leung，Nancy Hsu，et al. Heparin protects against septic mortality via apoE-antagonism［J］. American J Surg，2011，202（3）：325-335.
|
| 21 |
Kumaraswamy SB，Linder A，Akesson P，et al. Decreased plasma concentrations of apolipoprotein M in sepsis and systemic inflammatory response syndromes［J］. Crit Care，2012，16（2）：11 93-1 2 0 3.
|
| 22 |
石岩.严重脓毒症发病机制新认识［J］.中国实用外科杂志，2012，32（11）：956-958.
|
| 23 |
张柳，安友仲.中国危重病急救医学［J］.2011，23（8）：509-511.
|
| 24 |
Gräler MH. The role of sphingosine 1-phosphate in immunity and sepsis［J］.Am J Clin Exp Immunol，2012，1（2）：90-100.
|
| 25 |
Obinata H，Hla T. Sphingosine 1-phosphate in coagulation and inflammation［J］.Semin Immunopathol［J］.2012，34（1）：73-91.
|
| 26 |
Camerer E，Regard JB，Cornelissen I，et al. Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice［J］.J Clin Invest，2009，119（7）：1871-1879.
|
| 27 |
Sanchez T，Skoura A，Wu MT，et al.Timothy Hlalnduction of vascular permeability by the sphingosine-l-phosphate receptor-2 （S1P2R）and its downstream effectors ROCK and PTEN［J］. Arterioscler Thromb Vasc Biol，2007，27（6）：1312-1318.
|
| 28 |
Sammani S，Moreno-Vinasco L，Mirzapoiazova T，et al. Differential effects of SIP receptors on airway and vascular barrier function in the murine lung［J］.Am J Respir Cell Mol Biol，2010，43（4）：394-402.
|
| 29 |
Zhang G，Xu S，Qian Y，et al. Sphingosine-l-phosphate prevents permeability increases via activation of endothelial sphingosinel-phosphate receptor 1 in rat venules［J］. Am J Physiol Heart Circ Physiol，2010，299（5）：H1494-1504.
|
| 30 |
Singleton PA，Moreno-Vinasco L，Sammani S，et al.Attenuation of vascular permeability by methylaltrexone role of mOP-R and S 1 P3 transactivation［J］. Am J Respirat Cell Mol Biol［J］. 2007，37（2）：2 2 2-2 3 1.
|
| 31 |
Shikata Y，Birukov KG，Garcia JG. SIP induces FA remodeling in human pulmonary endothelial cells： role of Rac，GIT1，FAK，and paxillin［J］.JAppl Physiol（1985），2003，94（3）：1193-1203.
|
| 32 |
Blaho VA，Hla T.Regulation of mammalian physiology，development，and disease by the sphingosine l-phosphate and lysophosphatidic acid receptors［J］.Chem Rev，2011，111（10）：6299-6320.
|